Denmark
# |
Name |
Debt to Equity Ratio |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
0.55
|
Dec. 31, 2023 | USD 54.16 | -1.39% |
|
Denmark |
|
2 |
0.19
|
Dec. 31, 2023 | USD 5.46 | 0.56% |
|
Denmark |
|
3 |
0.15
|
Dec. 31, 2023 | USD 91.43 | -1.85% |
|
Denmark |
|
4 |
0.12
|
Dec. 31, 2023 | USD 0.20 | -2.77% |
|
Denmark |
|
5 |
0.07
|
Dec. 31, 2023 | USD 95.84 | 0.08% |
|
Denmark |
|
6 |
0.03
|
Dec. 31, 2023 | USD 2.17 | 5.88% |
|
Denmark |
|
7 |
0.02
|
Dec. 31, 2023 | USD 216.88 | 1.28% |
|
Denmark |
|
8 |
0.01
|
Dec. 31, 2023 | USD 26.62 | -0.36% |
|
Denmark |
|
9 |
0.01
|
June 30, 2024 | USD 70.50 | 0.61% |
|
Denmark |
|
10 |
-3.25
|
Dec. 31, 2023 | USD 0.57 | 1.47% |
|
Denmark |
|
11 |
-4.42
|
Dec. 31, 2023 | USD 131.57 | -1.84% |
|
Denmark |
The Biotechnology company in Denmark with the highest Debt to Equity Ratio is Novozymes A/S (Copenhagen Stock Exchange: NSIS-B.CO) at 0.55.
The Biotechnology company in Denmark with the lowest Debt to Equity Ratio is Ascendis Pharma A/S (NasdaqGS: ASND) at -4.42.
The top 10 Biotechnology companies in Denmark by Debt to Equity Ratio are Novozymes A/S, H. Lundbeck A/S, Gubra A/S, BioPorto A/S, Zealand Pharma A/S, ExpreS2ion Biotech Holding AB (publ), Genmab A/S, Bavarian Nordic A/S, ChemoMetec A/S and Saniona AB (publ).
The bottom 10 Biotechnology companies in Denmark by Debt to Equity Ratio are Ascendis Pharma A/S, Saniona AB (publ), ChemoMetec A/S, Bavarian Nordic A/S, Genmab A/S, ExpreS2ion Biotech Holding AB (publ), Zealand Pharma A/S, BioPorto A/S, Gubra A/S and H. Lundbeck A/S.